ClinicalTrials.gg
TerminatedNCT00134238RADIANCE 2Updated Feb 17, 2012

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Mixed Hyperlipidemia, sponsored by Pfizer. Terminated at 51 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.

Enrollment
9th of 68
755 · median 163
Started
2003
with 5 others
Phase 3
30 of 76
5 open now
Registered
4th of 76
by date
Lead sponsor
5 of 76
Pfizer

Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 9th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2003, is one of 30 in phase 3, and was the 4th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hyperlipoproteinemia Type II with a site in United States, or all of them as a file.
02

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia

Read the detailed description

For additional information please call: 1-800-718-1021

03

Conditions studied

  • Mixed Hyperlipidemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of mixed hyperlipidemia
  • At least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
755 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in intima media thickness as measured by carotid ultrasound

Secondary outcomes

  1. Changes in levels of lipids and other biomarkers.

07

Study locations

51 sites
  • Pfizer Investigational Site
    Gilbert, Arizona, United States
  • Pfizer Investigational Site
    Phoenix, Arizona, United States
  • Pfizer Investigational Site
    Scottsdale, Arizona, United States
  • Pfizer Investigational Site
    Alhambra, California, United States
  • Pfizer Investigational Site
    Encinitas, California, United States
  • Pfizer Investigational Site
    La Jolla, California, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    San Diego, California, United States
  • Pfizer Investigational Site
    Hartford, Connecticut, United States
  • Pfizer Investigational Site
    Melbourne, Florida, United States
  • Pfizer Investigational Site
    Palm Bay, Florida, United States
  • Pfizer Investigational Site
    Sebastian, Florida, United States
  • Pfizer Investigational Site
    Stuart, Florida, United States
  • Pfizer Investigational Site
    Vero Beach, Florida, United States
  • Pfizer Investigational Site
    Overland Park, Kansas, United States
  • Pfizer Investigational Site
    Boston, Massachusetts, United States
  • Pfizer Investigational Site
    Cambridge, Massachusetts, United States
  • Pfizer Investigational Site
    Edina, Minnesota, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota, United States
  • Pfizer Investigational Site
    Kansas City, Missouri, United States
  • Pfizer Investigational Site
    Concord, New Hampshire, United States
  • Pfizer Investigational Site
    Bronxville, New York, United States
  • Pfizer Investigational Site
    Buffalo, New York, United States
  • Pfizer Investigational Site
    Mount Vernon, New York, United States
  • Pfizer Investigational Site
    New York, New York, United States
  • Pfizer Investigational Site
    Williamsville, New York, United States
  • Pfizer Investigational Site
    Durham, North Carolina, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio, United States
  • Pfizer Investigational Site
    Houston, Texas, United States
  • Pfizer Investigational Site
    San Antonio, Texas, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah, United States
  • Pfizer Investigational Site
    Newport News, Virginia, United States
  • Pfizer Investigational Site
    Norfolk, Virginia, United States
  • Pfizer Investigational Site
    Richmond, Virginia, United States
  • Pfizer Investigational Site
    Bothell, Washington, United States
  • Pfizer Investigational Site
    Kirkland, Washington, United States
  • Pfizer Investigational Site
    Renton, Washington, United States
  • Pfizer Investigational Site
    Seattle, Washington, United States
  • Pfizer Investigational Site
    Vancouver, British Columbia, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec, Canada
  • Pfizer Investigational Site
    Montreal, Quebec, Canada
  • Pfizer Investigational Site
    Quebec, Canada
  • Pfizer Investigational Site
    Prague 4, Czech Republic
  • Pfizer Investigational Site
    Kuopio, Finland
  • Pfizer Investigational Site
    Paris Cedex, France
  • Pfizer Investigational Site
    Nijmegen, Netherlands
  • Pfizer Investigational Site
    Rotterdam, Netherlands
  • Pfizer Investigational Site
    Utrecht, Netherlands
08

References and documents

Publications

  • Tajik P, Meijer R, Duivenvoorden R, Peters SA, Kastelein JJ, Visseren FJ, Crouse JR 3rd, Palmer MK, Raichlen JS, Grobbee DE, Bots ML. Asymmetrical distribution of atherosclerosis in the carotid artery: identical patterns across age, race, and gender. Eur J Prev Cardiol. 2012 Aug;19(4):687-97. doi: 10.1177/1741826711410821. Epub 2011 May 25. PubMed 21613319 ↗
  • Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum In: Circulation. 2009 Feb 10;119(5):e197. PubMed 19029469 ↗
  • Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007 Jul 14;370(9582):153-160. doi: 10.1016/S0140-6736(07)61088-5. PubMed 17630038 ↗
  • Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML; RADIANCE 1 and 2 Study Investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin. 2007 Apr;23(4):885-94. doi: 10.1185/030079907x182121. PubMed 17407645 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2005
First posted
Aug 24, 2005
Start
Nov 2003
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results delay requested
Feb 15, 2012
Last update
Feb 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00134238
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 24, 2005
Start date
Nov 2003
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Feb 17, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin

Start the discussion